183 related articles for article (PubMed ID: 29623653)
1. Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease.
Vande Casteele N; Oyamada J; Shimizu C; Best BM; Capparelli EV; Tremoulet AH; Burns JC
Clin Pharmacokinet; 2018 Dec; 57(12):1593-1601. PubMed ID: 29623653
[TBL] [Abstract][Full Text] [Related]
2. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
3. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
Wang L; He M; Wang W; Li S; Zhao G
Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
[TBL] [Abstract][Full Text] [Related]
5. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
[TBL] [Abstract][Full Text] [Related]
6. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
Sakai H; Iwashima S; Sano S; Akiyama N; Nagata E; Harazaki M; Fukuoka T
Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
[TBL] [Abstract][Full Text] [Related]
7. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
8. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
Dionne A; Burns JC; Dahdah N; Tremoulet AH; Gauvreau K; de Ferranti SD; Baker AL; Son MB; Gould P; Fournier A; Newburger JW; Friedman KG
Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31048414
[TBL] [Abstract][Full Text] [Related]
9. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Burns JC; Best BM; Mejias A; Mahony L; Fixler DE; Jafri HS; Melish ME; Jackson MA; Asmar BI; Lang DJ; Connor JD; Capparelli EV; Keen ML; Mamun K; Keenan GF; Ramilo O
J Pediatr; 2008 Dec; 153(6):833-8. PubMed ID: 18672254
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
11. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive therapies in Kawasaki disease.
Tremoulet AH
Int J Rheum Dis; 2018 Jan; 21(1):76-79. PubMed ID: 29076637
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and Treatment Trends in Children With Kawasaki Disease in the United States, 2006-2015.
Dominguez SR; Birkholz M; Anderson MS; Heizer H; Jone PN; Glode MP; Todd JK
Pediatr Infect Dis J; 2019 Oct; 38(10):1010-1014. PubMed ID: 31365480
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
15. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
Kuwabara M; Yashiro M; Ae R; Yanagawa H; Nakamura Y
Int J Cardiol; 2018 Oct; 269():334-338. PubMed ID: 30049499
[TBL] [Abstract][Full Text] [Related]
16. Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?
Davies S; Gold-von Simson G
Pediatr Cardiol; 2013 Oct; 34(7):1756. PubMed ID: 23771701
[No Abstract] [Full Text] [Related]
17. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
Son MB; Gauvreau K; Burns JC; Corinaldesi E; Tremoulet AH; Watson VE; Baker A; Fulton DR; Sundel RP; Newburger JW
J Pediatr; 2011 Apr; 158(4):644-649.e1. PubMed ID: 21129756
[TBL] [Abstract][Full Text] [Related]
18. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
19. Impact of infliximab administration before plasma exchange therapy on patients with Kawasaki disease.
Shimada S; Matsuoka D; Murase T; Hachiya A; Motoki N; Nakazawa Y
Ther Apher Dial; 2020 Dec; 24(6):718-724. PubMed ID: 32077249
[TBL] [Abstract][Full Text] [Related]
20. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
Youn Y; Kim J; Hong YM; Sohn S
Pediatr Infect Dis J; 2016 Apr; 35(4):457-9. PubMed ID: 26673981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
